Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis - PubMed
3 hours ago
- #ovarian cancer
- #PARP inhibitors
- #real-world data
- PARP inhibitors (olaparib and niraparib) are first-line maintenance therapy for advanced epithelial ovarian cancer (EOC) post platinum-based chemotherapy.
- A retrospective study of 179 EOC patients in Türkiye showed durable progression-free survival (PFS) benefits, especially in BRCA-mutant patients.
- PFS rates at 6, 12, and 24 months were 91%, 83%, and 64% respectively for the overall cohort.
- BRCA-mutant patients had better PFS outcomes, with pathogenic variants showing longer PFS than likely pathogenic variants.
- Adverse events occurred in 73.7% of patients, with 29.6% being grade 3-4, primarily hematologic toxicities.
- Dose interruptions were more common with niraparib, but discontinuation rates were low for both drugs.
- No cases of myelodysplastic syndrome or acute myeloid leukemia were reported.
- The study confirms the effectiveness and manageable safety of PARP inhibitors in real-world clinical practice.